Skip to main content
Top
Published in: BMC Medical Genetics 1/2017

Open Access 01-12-2017 | Research article

PEAR1 is not a major susceptibility gene for cardiovascular disease in a Flemish population

Authors: Wen-Yi Yang, Thibault Petit, Nicholas Cauwenberghs, Zhen-Yu Zhang, Chang-Sheng Sheng, Lutgarde Thijs, Erika Salvi, Benedetta Izzi, Christophe Vandenbriele, Fang-Fei Wei, Yu-Mei Gu, Lotte Jacobs, Lorena Citterio, Simona Delli Carpini, Cristina Barlassina, Daniele Cusi, Marc F. Hoylaerts, Peter Verhamme, Tatiana Kuznetsova, Jan A. Staessen

Published in: BMC Medical Genetics | Issue 1/2017

Login to get access

Abstract

Background

Platelet Endothelial Aggregation Receptor 1 (PEAR1), a membrane protein highly expressed in platelets and endothelial cells, plays a role in platelet contact-induced activation, sustained platelet aggregation and endothelial function. Previous reports implicate PEAR1 rs12041331 as a variant influencing risk in patients with coronary heart disease. We investigated whether genetic variation in PEAR1 predicts cardiovascular outcome in a white population.

Methods

In 1938 participants enrolled in the Flemish Study on Environment, Genes and Health Outcomes (51.3% women; mean age 43.6 years), we genotyped 9 tagging SNPs in PEAR1, measured baseline cardiovascular risk factors, and recorded Cardiovascular disease incidence. For SNPs, we contrasted cardiovascular disease incidence of minor-allele heterozygotes and homozygotes (variant) vs. major-allele homozygotes (reference) and for haplotypes carriers vs. non-carriers. In adjusted analyses, we accounted for family clusters and baseline covariables, including sex, age, body mass index, mean arterial pressure, the total-to-HDL cholesterol ratio, smoking and drinking, antihypertensive drug treatment, and history of cardiovascular disease and diabetes mellitus.

Results

Over a median follow-up of 15.3 years, 238 died and 181 experienced a major cardiovascular endpoint. The multivariable-adjusted hazard ratios of eight PEAR1 SNPs, including rs12566888, ranged from 0.87 to 1.07 (P ≥0.35) and from 0.78 to 1.30 (P ≥0.15), respectively. The hazard ratios of three haplotypes with frequency ≥10% ranged from 0.93 to 1.11 (P ≥0.49) for mortality and from 0.84 to 1.03 (P ≥0.29) for a cardiovascular complications. These results were not influenced by intake of antiplatelet drugs, nonsteroidal anti-inflammatory drugs, or both (P-values for interaction ≥ 0.056).

Conclusions

In a White population, we could not replicate previous reports from experimental studies or obtained in patients suggesting that PEAR1 might be a susceptibility gene for cardiovascular complications.
Appendix
Available only for authorised users
Literature
1.
go back to reference Nanda N, Bao M, Lin H, Clauser K, Komuves L, Quertermous T, et al. Platelet endothelial aggregation receptor 1 (PEAR1), a novel epidermal growth factor repeat-containing transmembrane receptor, participates in platelet contact-induced activation. J Biol Chem. 2005;280:24680–9.CrossRefPubMed Nanda N, Bao M, Lin H, Clauser K, Komuves L, Quertermous T, et al. Platelet endothelial aggregation receptor 1 (PEAR1), a novel epidermal growth factor repeat-containing transmembrane receptor, participates in platelet contact-induced activation. J Biol Chem. 2005;280:24680–9.CrossRefPubMed
2.
go back to reference Kauskot A, Di Michele M, Loyen S, Freson K, Verhamme P, Hoylaerts MF. A novel mechanism of sustained platelet αIIbβ3 activation via PEAR1. Blood. 2012;119:4056–65.CrossRefPubMed Kauskot A, Di Michele M, Loyen S, Freson K, Verhamme P, Hoylaerts MF. A novel mechanism of sustained platelet αIIbβ3 activation via PEAR1. Blood. 2012;119:4056–65.CrossRefPubMed
3.
go back to reference Qayyum R, Becher LC, Becher DM, Faraday N, Yanek LR, Leal SM, et al. Genome-wide association study of platelet aggregation in African Americans. BMC Genet. 2015;16:58–68.CrossRefPubMedPubMedCentral Qayyum R, Becher LC, Becher DM, Faraday N, Yanek LR, Leal SM, et al. Genome-wide association study of platelet aggregation in African Americans. BMC Genet. 2015;16:58–68.CrossRefPubMedPubMedCentral
4.
go back to reference Johnson AD, Yanek LR, Chen MH, Faraday N, Larson MG, Tofler G, et al. Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nat Genet. 2010;42:608–13.CrossRefPubMedPubMedCentral Johnson AD, Yanek LR, Chen MH, Faraday N, Larson MG, Tofler G, et al. Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nat Genet. 2010;42:608–13.CrossRefPubMedPubMedCentral
5.
go back to reference Lewis JP, Ryan K, O’Connell JR, Horenstein RB, Damcott CM, Gibson Q, et al. Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. Circ Cardiovasc Genet. 2013;6:184–92.CrossRefPubMedPubMedCentral Lewis JP, Ryan K, O’Connell JR, Horenstein RB, Damcott CM, Gibson Q, et al. Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. Circ Cardiovasc Genet. 2013;6:184–92.CrossRefPubMedPubMedCentral
6.
go back to reference Xiang Q, Cui Y, Zhao X, Zhao N. Identification of PEAR1 SNPs and their influences on the variation in prasugrel pharmacodynamics. Pharmacogenomics. 2013;14:1179–89.CrossRefPubMed Xiang Q, Cui Y, Zhao X, Zhao N. Identification of PEAR1 SNPs and their influences on the variation in prasugrel pharmacodynamics. Pharmacogenomics. 2013;14:1179–89.CrossRefPubMed
7.
go back to reference Vandenbriele C, Kauskot A, Vandersmissen I, Criel M, Geenens R, Craps S, et al. Platelet endothelial aggregation receptor-1: A novel modifier of neoangiogenesis. Cardiovasc Res. 2015;108:124–38.CrossRefPubMed Vandenbriele C, Kauskot A, Vandersmissen I, Criel M, Geenens R, Craps S, et al. Platelet endothelial aggregation receptor-1: A novel modifier of neoangiogenesis. Cardiovasc Res. 2015;108:124–38.CrossRefPubMed
8.
go back to reference Fisch AS, Yerges-Armstrong LM, Bachman JD, Wang H, Donnelly P, Ryan KA, et al. Genetic variation in the platelet endothelial aggregation receptor 1 gene results in endothelial dysfunction. PLoS ONE. 2015;10:e0138795.CrossRefPubMedPubMedCentral Fisch AS, Yerges-Armstrong LM, Bachman JD, Wang H, Donnelly P, Ryan KA, et al. Genetic variation in the platelet endothelial aggregation receptor 1 gene results in endothelial dysfunction. PLoS ONE. 2015;10:e0138795.CrossRefPubMedPubMedCentral
9.
go back to reference Shechter M, Shechter A, Koren-Morag N, Feinberg MS, Hiersch L. Usefulness of brachial artery flow-mediated dilatation to predict long-term cardiovascular events in subjects without heart disease. Am J Cardiol. 2014;113:162–7.CrossRefPubMed Shechter M, Shechter A, Koren-Morag N, Feinberg MS, Hiersch L. Usefulness of brachial artery flow-mediated dilatation to predict long-term cardiovascular events in subjects without heart disease. Am J Cardiol. 2014;113:162–7.CrossRefPubMed
10.
go back to reference Staessen JA, Wang JG, Brand E, Barlassina C, Birkenhäger WH, Herrmann SM, et al. Effects of three candidate genes on prevalence and incidence of hypertension in a Caucasian population. J Hypertens. 2001;19:1349–58.CrossRefPubMed Staessen JA, Wang JG, Brand E, Barlassina C, Birkenhäger WH, Herrmann SM, et al. Effects of three candidate genes on prevalence and incidence of hypertension in a Caucasian population. J Hypertens. 2001;19:1349–58.CrossRefPubMed
11.
go back to reference Li Y, Zagato L, Kuznetsova T, Tripodi G, Zerbini G, Richart T, et al. Angiotensin-converting enzyme I/D and α-adducin Gly460Trp polymorphisms. From angiotensin-converting enzyme activity to cardiovascular outcome. Hypertension. 2007;49:1291–7.CrossRefPubMed Li Y, Zagato L, Kuznetsova T, Tripodi G, Zerbini G, Richart T, et al. Angiotensin-converting enzyme I/D and α-adducin Gly460Trp polymorphisms. From angiotensin-converting enzyme activity to cardiovascular outcome. Hypertension. 2007;49:1291–7.CrossRefPubMed
12.
go back to reference Yang WY, Petit T, Thijs L, Zhang ZY, Jacobs L, Hara A, et al. Coronary risk in relation to genetic variation in MEOX2 and TCF15 in a Flemish population. BMC Genet. 2015;16:116.CrossRefPubMedPubMedCentral Yang WY, Petit T, Thijs L, Zhang ZY, Jacobs L, Hara A, et al. Coronary risk in relation to genetic variation in MEOX2 and TCF15 in a Flemish population. BMC Genet. 2015;16:116.CrossRefPubMedPubMedCentral
13.
go back to reference Citterio L, Simonini M, Zagato L, Salvi E, Delli Carpini S, Lanzani C, et al. Genes involved in vasoconstriction and vasodilation affect salt-sensitive hypertension. PLoS One. 2011;6:e19620.CrossRefPubMedPubMedCentral Citterio L, Simonini M, Zagato L, Salvi E, Delli Carpini S, Lanzani C, et al. Genes involved in vasoconstriction and vasodilation affect salt-sensitive hypertension. PLoS One. 2011;6:e19620.CrossRefPubMedPubMedCentral
14.
go back to reference Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet. 2012;44:955–9.CrossRefPubMedPubMedCentral Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet. 2012;44:955–9.CrossRefPubMedPubMedCentral
15.
go back to reference Faraday N, Yanek LR, Yang XP, Mathias RA, Herrera-Galeano JE, Suktitipat B, et al. Identification of a specific intronic PEAR1 gene variant associated with greater platelet aggregability and protein expression. Blood. 2011;118:3367–75.CrossRefPubMedPubMedCentral Faraday N, Yanek LR, Yang XP, Mathias RA, Herrera-Galeano JE, Suktitipat B, et al. Identification of a specific intronic PEAR1 gene variant associated with greater platelet aggregability and protein expression. Blood. 2011;118:3367–75.CrossRefPubMedPubMedCentral
16.
go back to reference Jones CI, Bray S, Garner SF, Stephens J, de Bono B, Angenent WGJ, et al. A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways. Blood. 2009;114:1405–16.CrossRefPubMed Jones CI, Bray S, Garner SF, Stephens J, de Bono B, Angenent WGJ, et al. A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways. Blood. 2009;114:1405–16.CrossRefPubMed
17.
go back to reference Herrera-Galeano JE, Becher DM, Wilson AF, Yanek LR, Bray P, Vaidya D, et al. A novel variant in the platelet endothelial aggregation receptor-1 gene is associated with increased platelet aggregability. Arterioscler Thromb Vasc Biol. 2008;28:1484–90.CrossRefPubMedPubMedCentral Herrera-Galeano JE, Becher DM, Wilson AF, Yanek LR, Bray P, Vaidya D, et al. A novel variant in the platelet endothelial aggregation receptor-1 gene is associated with increased platelet aggregability. Arterioscler Thromb Vasc Biol. 2008;28:1484–90.CrossRefPubMedPubMedCentral
18.
go back to reference Wurtz M, Nissen PH, Grove EL, Kristensen SD, Hvas AM. Genetic determinants of on-aspirin platelet reactivity: focus on the influence of PEAR1. PLoS ONE. 2014;9:e111816.CrossRefPubMedPubMedCentral Wurtz M, Nissen PH, Grove EL, Kristensen SD, Hvas AM. Genetic determinants of on-aspirin platelet reactivity: focus on the influence of PEAR1. PLoS ONE. 2014;9:e111816.CrossRefPubMedPubMedCentral
19.
go back to reference Kim Y, Suktitipat B, Yanek LR, Faraday N, Wilson AF, Becker DM, et al. Targeted deep resequencing idetifies coding variants in the PEAR1 gene that play a role in platelet aggregation. PLoS ONE. 2013;8:1–8.CrossRef Kim Y, Suktitipat B, Yanek LR, Faraday N, Wilson AF, Becker DM, et al. Targeted deep resequencing idetifies coding variants in the PEAR1 gene that play a role in platelet aggregation. PLoS ONE. 2013;8:1–8.CrossRef
20.
go back to reference Voora D, Horton J, Shah SH, Shaw LK, Newby LK. Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use. Am Heart J. 2011;162:166–72.CrossRefPubMed Voora D, Horton J, Shah SH, Shaw LK, Newby LK. Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use. Am Heart J. 2011;162:166–72.CrossRefPubMed
21.
go back to reference Gorog DA, Sweenly JM, Fuster V. Antiplatelet drug ‘resistance’. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact? Nat Rev Cardiol. 2009;6:365–73.PubMed Gorog DA, Sweenly JM, Fuster V. Antiplatelet drug ‘resistance’. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact? Nat Rev Cardiol. 2009;6:365–73.PubMed
22.
go back to reference Gorog DA, Fuster V. Platelet function tests in clinical cardiology: unfulfilled expectations. J Am Coll Cardiol. 2013;61:2115–29.CrossRefPubMed Gorog DA, Fuster V. Platelet function tests in clinical cardiology: unfulfilled expectations. J Am Coll Cardiol. 2013;61:2115–29.CrossRefPubMed
23.
go back to reference Current-Oasis 7 Investigators, Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363:930–42.CrossRef Current-Oasis 7 Investigators, Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363:930–42.CrossRef
24.
go back to reference Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. J Am Med Assoc. 2011;305:1097–105.CrossRef Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. J Am Med Assoc. 2011;305:1097–105.CrossRef
25.
go back to reference Ginsel B, Aggarwal A, Xuan W, Harris I. The distribution of probability values in medical abstracts: an obvervational study. BMC Res Notes. 2015;8:721.CrossRefPubMedPubMedCentral Ginsel B, Aggarwal A, Xuan W, Harris I. The distribution of probability values in medical abstracts: an obvervational study. BMC Res Notes. 2015;8:721.CrossRefPubMedPubMedCentral
Metadata
Title
PEAR1 is not a major susceptibility gene for cardiovascular disease in a Flemish population
Authors
Wen-Yi Yang
Thibault Petit
Nicholas Cauwenberghs
Zhen-Yu Zhang
Chang-Sheng Sheng
Lutgarde Thijs
Erika Salvi
Benedetta Izzi
Christophe Vandenbriele
Fang-Fei Wei
Yu-Mei Gu
Lotte Jacobs
Lorena Citterio
Simona Delli Carpini
Cristina Barlassina
Daniele Cusi
Marc F. Hoylaerts
Peter Verhamme
Tatiana Kuznetsova
Jan A. Staessen
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Medical Genetics / Issue 1/2017
Electronic ISSN: 1471-2350
DOI
https://doi.org/10.1186/s12881-017-0411-x

Other articles of this Issue 1/2017

BMC Medical Genetics 1/2017 Go to the issue